| Literature DB >> 27297459 |
Pascal M W Drake1, Tim H Szeto1, Mathew J Paul1, Audrey Y-H Teh1, Julian K-C Ma1.
Abstract
Biotechnology has transformed the potential for plants to be a manufacturing source of pharmaceutical compounds. Now, with transgenic and transient expression techniques, virtually any biologic, including vaccines and therapeutics, could be manufactured in plants. However, uncertainty over the regulatory path for such new pharmaceuticals has been a deterrent. Consideration has been given to using alternative regulatory paths, including those for nutraceuticals or cosmetic agents. This review will consider these possibilities, and discuss the difficulties in establishing regulatory guidelines for new pharmaceutical manufacturing technologies.Keywords: GMP; manufacturing; monoclonal antibody; recombinant pharmaceutical; transgenic plants
Mesh:
Substances:
Year: 2016 PMID: 27297459 PMCID: PMC5338133 DOI: 10.1111/bcp.13041
Source DB: PubMed Journal: Br J Clin Pharmacol ISSN: 0306-5251 Impact factor: 4.335